Medical network - on May 31, according to the China urology disease diagnosis and treatment guidelines, 2014 edition, urology disease is divided into: tumor mainly includes: renal cell carcinoma, bladder, prostate, testicular cancer and penile cancer; The stone; The disorders of prostatic hyperplasia and urinary dysfunction are mainly divided into three segments: benign prostatic hyperplasia, neurogenic bladder and hyperactivity of the bladder. And finally, some infections of the urinary system. 

 

Due to tumor drug drug use is of a special field, stone mainly through the surgery to treat, urinary tract infection is the conventional scheme of anti-infection drugs, so this article discussed in the urinary tract preparation mainly concentrated in the third class, the hyperplasia of prostate and voiding dysfunction in the field of medicine. 

 

Americans about urinary system medicine, always think of putian male with hospital, they started with from the field in this area for profiteering. The bombardment of advertising and the false propaganda made the medicine of the field dissected from the scientific realm of reason. 

 

However, from the point of epidemiological situation, benign hyperplasia of prostate and bladder disease as well as the high incidence of urinary incontinence not only excessive activity, and seriously affect the quality of life. According to epidemiological data published in 2011, China bladder disease in the overall prevalence of 6.0%, excessive activity of female prevalence was 6.0%, 5.9% of men, and in more than 40 people. 

 

Though small, there is also a heavy medicine. However, in the case of research and development, domestic pharmaceutical companies are genuinely concerned about the market. 

 

1 [clinical need] 

 

Morbidity, TOP 3 disease 

 

Benign prostatic hyperplasia 

 

Benign prostatic hyperplasia (BPH) is a common progressive disease that can significantly affect the quality of life in older men. BPH clinical treatment includes drug therapy and surgical treatment. For most patients who do not have surgery, medication is the primary treatment. 

 

The cause of BPH is not yet clear. The vast majority of the view is that there are two necessary conditions for the disease -- age and functional testes. The current mechanism for BPH is not clear, probably due to the proliferation of epithelial and interstitial cells and the balance of apoptosis. 

 

BPH main show is histologically hyperplasia of prostate stromal and glandular components, enlargement of the prostate gland in anatomical, urine dynamics of bladder outlet obstruction and urinary tract symptoms. 

 

Current BPH drugs include alpha blockers, 5 alpha reductase blockers (5ARI), M blockers, and plant preparation. 

 

Neurogenic bladder 

 

Neurogenic bladder, it is because the neural control mechanism under the turbulence caused by urinary tract dysfunction, often under the premise of a neuropathy to diagnosis. All of the diseases that may affect the bladder and/or urinary tract regulation may cause bladder and (or) urethral dysfunction. There is no reliable statistical data on the clinical performance of neurogenic cystis and the location and extent of nerve damage. The main use of physiotherapy is the limited use of single drug treatment, and only combination therapy can achieve the maximum effect. 

 

Currently, the drugs in the treatment range mainly include M receptor blockers, alpha blockers, alpha receptor agonists, and ammonia vasopressin. 

 

Hyperactivity of the bladder 

 

Bladder hyperactivity disorder refers to the syndromes of clinical manifestations, such as the acute symptoms of urea, urinary frequency and emergency incontinence. Often accompanied by frequent urination and nocturia, with or without urgent urinary incontinence, no urinary tract infection or other specific pathological changes. 

 

The current treatment is mostly m. receptor blockers, mainly totrodine and solly.